Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients

por Salem, Ahmed M., Mugundu, Ganesh M., Singh, Aman P.
Publicado 2023

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

por Dey, Agnish, Austin, Matthew, Kluger, Harriet M., Trunova, Nataliya, Mann, Helen, Shire, Norah, Morgan, Claire, Zhou, Diansong, Mugundu, Ganesh M.
Publicado 2022

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

por Falchook, Gerald S, Sachdev, Jasgit, Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh M, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David R, Johnson, Melissa
Publicado 2023

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study

por Kato, Hidenori, de Souza, Paul, Kim, Sang-We, Lickliter, Jason D., Naito, Yoichi, Park, Keunchil, Kumar, Sanjeev, Mugundu, Ganesh M., Bang, Yung-Jue
Publicado 2020

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

por Någård, Mats, Ah-See, Mei-Lin, Strauss, James, Wise-Draper, Trisha, Safran, Howard P., Nadeau, Laura, Edenfield, William J., Lewis, Lionel D., Ottesen, Lone H., Li, Yan, Mugundu, Ganesh M.
Publicado 2023

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study

por Någård, Mats, Ah-See, Mei-Lin, Strauss, James, Wise-Draper, Trisha, Safran, Howard P., Nadeau, Laura, Edenfield, William J., Lewis, Lionel D., Rekić, Dinko, Dota, Corina, Ottesen, Lone H., Li, Yan, Mugundu, Ganesh M.
Publicado 2023